...

AN OPEN-LABEL, NONRANDOMIZED, MULTICENTER EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN PARTICIPANTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS

Establish the long-term safety and efficacy of pegcetacoplan in participants with C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)


Why this Research Matters

An Open-Label, nonrandomized, extension study to evaluate long-term safety and efficacy of pegcetacoplan in patients with C3G or IC-MPGN


Who can Participate

All Ages

Completion of APL310 Study, willing to comply with birth control requirements.


Study ID

Protocol Number: 23-2113

Meet the Team

Image of Principal Investigator

Bradley Dixon, MD

Principal Investigator